Rosiglitazone ameliorates DKD by maintaining kidney function and inhibiting the production of pro-inflammatory cytokines by inhibiting ACSL4 and blocking renal tubular cell ferroptosis (23). The gene discussed is ACSL4; the disease is diabetic kidney disease.